drugset / Trial / NCT01573910

An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients

NCT01573910

Phase 3 Completed 985 enrolled Alcon Research
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to evaluate Moxifloxacin 0.5% relative to Ofloxacin 0.3% in the treatment of bacterial conjunctivitis in Chinese patients.

Timeline

Start
2012-05
Primary completion
2014-04
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Moxifloxacin Small molecule 0.5 % Topical
Comparator Ofloxacin Small molecule 0.3 % Topical